Novacea slows down development program for AQ4N

Novacea, which is burning through $17 million to $19 million this year, says it will scale back on the development of AQ4N, shelving a clinical trial in acute lymphoblastic leukemia and delaying a clinical trial in B-cell lymphoma. The news was included in a strategic review of its plans for 2008. An ongoing Phase Ib/IIa clinical trial of AQ4N in patients with glioblastoma multiforme will continue.

"Since we terminated the ASCENT-2 trial in advanced prostate cancer, managing our capital resources, which totaled approximately $110 million in cash and receivables at the end of the third quarter of 2007, is a top priority as we seek to maximize the strategic options available to the company," says Novacea CEO John Walker.

- see Novacea's release
- read the report from Trading Markets

Suggested Articles

Peter Doshi has penned an opinion piece in the BMJ pointing out that current COVID-19 vaccine tests are not set up to save lives.

You may have heard of T cells before, but Aleks Radovic-Moreno, Be Biopharma’s co-founder, is betting on B cells as the future of cell therapies.

Doctors may prescribe steroids or eye drops for patients with dry eye disease. But Azura Ophthalmics wants to do one better.